We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Circio Holding Asa | LSE:0RIS | London | Ordinary Share | NO0013033795 | CIRCIO HOLDING ORD SHS |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 15.98 | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Home Health Care Services | 10M | -432.9M | -2.2969 | -6.96 | 3.01B |
OSLO, Norway, Aug. 18, 2021 /PRNewswire/ -- Targovax ASA (OSE: TRVX), a clinical stage biotechnology company developing immune activators to target hard-to-treat solid tumors, today announces its second quarter and first half year 2021 results.
Targovax's management will give an online presentation and update on the clinical program to investors, analysts and the press at 10:00 CET today (details below).
FIRST HALF YEAR HIGHLIGHTS
FINANCIALS - KEY FIGURES
Amounts in NOK thousands | 2Q 2021 | 2Q 2020 | 1H 2021 | 1H 2020 | FY 2020 |
Total operating revenues | 272 | 590 | 624 | ||
Total operating expenses | -24 529 | -29 985 | -47 539 | -59 579 | -104 524 |
Operating profit/loss | -24 529 | -29 713 | -47 539 | -58 989 | -103 901 |
Net financial items | -1 026 | -3 649 | -513 | -371 | -4 503 |
Income tax | 15 | 71 | 31 | 147 | 277 |
Net profit/loss | -25 539 | -33 291 | -48 020 | -59 214 | -108 126 |
Basic and diluted EPS (NOK/share) | -0.30 | -0.44 | -0.55 | -0.80 | -1.40 |
Net change in cash | -24 276 | -33 824 | -51 130 | 31 036 | 51 893 |
Cash and cash equivalents start of period | 95 468 | 135 289 | 122 321 | 70 429 | 70 429 |
Cash and cash equivalents end of period | 71 192 | 101 465 | 71 192 | 101 465 | 122 321 |
The interim financial information has not been subject to audit.
The interim financial information has not been subject to audit.
Øystein Soug, CEO commented: "Targovax has conducted a broad early-stage clinical development program, documenting the clinical effects of ONCOS-102. We have shown promising and important benefits in patients without raising safety concerns. The main focus going forward is to take ONCOS-102 eagerly forward in clinical development in PD1-refractory melanoma. The feedback and discussions with the FDA have provided further guidance on what is the best next step, which will be a platform trial in PD1 refractory melanoma. The trial is intended to test ONCOS-102 in monotherapy and multiple combinations, including PD1 checkpoint inhibitor and potentially other novel immunotherapies to further enhance the efficacy beyond the promising response rate we saw in our previous melanoma trial. This will provide an opportunity to differentiate ONCOS-102 from other approaches and potentially open up development avenues into the commercially highly attractive front-line melanoma therapy indication."
Presentation
We invite to a live webcast today at 10.00 CET. You can join the webcast here. It will be possible to ask questions during the presentation.
Reporting materialTRVX Q2 reportTRVX Q2 presentation
The quarterly report and presentation are also available at the website www.targovax.com
For further information, please contact:
Oystein Soug, CEO
Phone: +47 906 56 525
Email: oystein.soug@targovax.com
Renate Birkeli, Investor Relations
Phone: +47 922 61 624
Email: renate.birkeli@targovax.com
Media enquires:
Andreas Tinglum - Corporate Communications (Norway)
Phone: +47 9300 1773
Email: andreas.tinglum@corpcom.no
This information was brought to you by Cision http://news.cision.com
https://news.cision.com/targovax/r/targovax-asa--second-quarter-and-first-half-year-2021-results,c3397894
The following files are available for download:
https://mb.cision.com/Public/17093/3397894/9aa98e1060a7fede.pdf | TRVX Q2 report |
https://mb.cision.com/Public/17093/3397894/a1f15ea8085fb74c.pdf | TRVX Q2 presentation |
View original content:https://www.prnewswire.com/news-releases/targovax-asa-second-quarter-and-first-half-year-2021-results-301357595.html
SOURCE Targovax
Copyright 2021 PR Newswire
1 Year Circio Holding Asa Chart |
1 Month Circio Holding Asa Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions